EGFR mutation and overexpression are closely related to tumorigenesis and development of non-small-cell lung cancer (NSCLC), which makes EGFR an important target for the design and development of antitumor agents.20–22. This evidence concerns the gene EGFR and non-small cell lung carcinoma.